The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Wen, Xiaoyun ^a,b   Klockow, Laurieann ^a,c   Nekorchuk, Michael ^a   Sharifi, Hamayun J ^a   de Noronha, Carlos M C ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b EMORY UNIVERSITY   (United States)

^c MARQUETTE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CULLIN; CULLIN 4; PROTEIN DCAF1; SINGLE STRAND SELECTIVE MONOFUNCTIONAL URACIL DNA GLYCOSIDASE 1; UNCLASSIFIED DRUG; URACIL DNA GLYCOSIDASE; URACIL DNA GLYCOSIDASE 2; VPR PROTEIN; CARRIER PROTEIN; CCNO PROTEIN, HUMAN; DNA GLYCOSYLTRANSFERASE; VPRBP PROTEIN, HUMAN;

ARTICLE; BIOACCUMULATION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; ACTIVE TRANSPORT; BIOLOGICAL MODEL; CELL STRAIN HEK293; GENE EXPRESSION REGULATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; TISSUE DISTRIBUTION; UPREGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; CARRIER PROTEINS; CELL NUCLEUS; DNA GLYCOSYLASES; GENE EXPRESSION REGULATION; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; TISSUE DISTRIBUTION; UP-REGULATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84856159248     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030939     Document Type: Article

References (41)

1. Wen X, Duus KM, Friedrich TD, de Noronha CM, (2007) The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 282: 27046-27057.
2. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, et al. (2007) HIV-1 Vpr-Mediated G2 Arrest Involves the DDB1-CUL4A(VPRBP) E3 Ubiquitin Ligase. PLoS Pathog 3: e85.
3. Tan L, Ehrlich E, Yu XF, (2007) DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 81: 10822-10830.
4. Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, et al. (2007) Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A 104: 11778-11783.
5. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, et al. (2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4: 57.
6. Schrofelbauer B, Hakata Y, Landau NR, (2007) HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci U S A 104: 4130-4135.
7. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, et al. (2007) HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6: 182-188.
8. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, et al. (2008) Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog 4: e1000057.
9. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, et al. (2008) Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 4: e1000059.
10. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658-661.
11. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature.
12. Singh SP, Lai D, Cartas M, Serio D, Murali R, et al. (2000) Epitope-tagging approach to determine the stoichiometry of the structural and nonstructural proteins in the virus particles: amount of vpr in relation to gag in HIV-1 [In Process Citation]. Virology 268: 364-371.
13. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, et al. (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2+M phase of the cell cycle. J Virol 69: 6304-6313.
14. Rogel ME, Wu LI, Emerman M, (1995) The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 69: 882-888.
15. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V, (2003) Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 278: 25879-25886.
16. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, et al. (1998) HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 4: 65-71.
17. Kewalramani VN, Park CS, Gallombardo PA, Emerman M, (1996) Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect. Virology 218: 326-334.
18. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR, (2005) Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 79: 10978-10987.
19. Bouhamdan M, Benichou S, Rey F, Navarro JM, Agostini I, et al. (1996) Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J Virol 70: 697-704.
20. Priet S, Gros N, Navarro JM, Boretto J, Canard B, et al. (2005) HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle. Mol Cell 17: 479-490.
21. Mansky LM, Preveral S, Selig L, Benarous R, Benichou S, (2000) The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J Virol 74: 7039-7047.
22. Yan N, O'Day E, Wheeler LA, Engelman A, Lieberman J, (2011) HIV DNA is heavily uracilated, which protects it from autointegration. Proc Natl Acad Sci U S A.
23. Norman JM, Mashiba M, McNamara LA, Onafuwa-Nuga A, Chiari-Fort E, et al. (2011) The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol 12: 975-983.
24. Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA, (2010) HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 115: 1354-1363.
25. Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, et al. (2009) HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog 5: e1000613.
26. Kaiser SM, Emerman M, (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol 80: 875-882.
27. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81: 7099-7110.
28. Ahn J, Vu T, Novince Z, Guerrero-Santoro J, Rapic-Otrin V, et al. (2010) HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J Biol Chem 285: 37333-37341.
29. Huang J, Chen J, (2008) VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation. Oncogene 27: 4056-4064.
30. Fischer JA, Muller-Weeks S, Caradonna S, (2004) Proteolytic degradation of the nuclear isoform of uracil-DNA glycosylase occurs during the S phase of the cell cycle. DNA Repair (Amst) 3: 505-513.
31. Hagen L, Kavli B, Sousa MM, Torseth K, Liabakk NB, et al. (2008) Cell cycle-specific UNG2 phosphorylations regulate protein turnover, activity and association with RPA. Embo J 27: 51-61.
32. Muller SJ, Caradonna S, (1993) Cell cycle regulation of a human cyclin-like gene encoding uracil-DNA glycosylase. J Biol Chem 268: 1310-1319.
33. Nagelhus TA, Slupphaug G, Lindmo T, Krokan HE, (1995) Cell cycle regulation and subcellular localization of the major human uracil-DNA glycosylase. Exp Cell Res 220: 292-297.
34. Selig L, Benichou S, Rogel ME, Wu LI, Vodicka MA, et al. (1997) Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J Virol 71: 4842-4846.
35. Jacquot G, Le Rouzic E, David A, Mazzolini J, Bouchet J, et al. (2007) Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology 4: 84.
36. BouHamdan M, Xue Y, Baudat Y, Hu B, Sire J, et al. (1998) Diversity of HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins. J Biol Chem 273: 8009-8016.
37. Jenkins Y, McEntee M, Weis K, Greene WC, (1998) Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways. J Cell Biol 143: 875-885.
38. Sherman MP, de Noronha CM, Heusch MI, Greene S, Greene WC, (2001) Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J Virol 75: 1522-1532.
39. Schuler W, Wecker K, de Rocquigny H, Baudat Y, Sire J, et al. (1999) NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions. J Mol Biol 285: 2105-2117.
40. Zhao LJ, Wang L, Mukherjee S, Narayan O, (1994) Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. J Biol Chem 269: 32131-32137.
41. Schreiber E, Matthias P, Muller MM, Schaffner W, (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419.